Sarepta Strengthens Pipeline Through Arrowhead Partnership for RNA Drugs

Sarepta Therapeutics has taken a significant strategic step by partnering with Arrowhead Pharmaceuticals, thereby enhancing its drug pipeline with advanced RNA drug development capabilities. Through this collaboration, Sarepta gains licensing rights to seven programs, including four clinical-stage treatments targeting complex conditions like facioscapulohumeral muscular dystrophy and idiopathic pulmonary fibrosis[1][2]. This alliance not only brings substantial cash inflows and equity investments, totaling $825 million, but also positions Sarepta at the forefront of developing siRNA-based therapies through Arrowhead's TRiM platform[2]. The partnership aims to diversify Sarepta’s offerings beyond its current Duchenne muscular dystrophy focus, looking towards diseases affecting the muscle, CNS, and lungs[3].